By Carlo Martuscelli

 

Novartis AG (NOVN.EB) said Monday that it will cease development of its investigational asthma drug fevipiprant following disappointing clinical data.

A pooled analysis of the Phase 3 Luster-1 and Luster-2 studies showed that the therapy didn't meet the clinical threshold in the reduction of moderate-to-severe asthma exacerbations when compared with placebo, the company said. The drug was, however, found safe, the Swiss drug maker said.

An analysis of safety and efficacy data from the two studies will be conducted, and details will be published at an upcoming medical conference, Novartis said.

 

Write to Carlo Martuscelli at carlo.martuscelli@wsj.com; @carlomartu

 

(END) Dow Jones Newswires

December 16, 2019 01:39 ET (06:39 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Novartis Charts.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Novartis Charts.